# J-Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/j-pharma

- Industry: Pharmaceuticals
- Headquarters: Tokyo, Japan
- Website: www.j-pharma.com
- Total disclosed funding: $67M
- Latest round: Series F (Jul 7, 2025)
- Investors on record: 28

## About

Founded in 2005 and based in Tokyo, Japan, J-Pharma Co., Ltd., d.b.a. J-Pharma, specializes in pharmaceutical development, focusing on SLC transporters to facilitate drug discovery. In March 2026, J-Pharma raised JPY 2.85 billion in an IPO, selling 3.24 million shares at JPY 880 per share at the Tokyo Stock Exchange, Growth market. The listing values J-Pharma at JPY 15.69 billion. J-Pharma specializes in the development of innovative pharmaceuticals targeting SLC transporters, particularly focusing on LAT1 (L-type amino acid transporter), which was discovered by the company's founder. The firm engages in the identification and analysis of promising transporters to facilitate drug discovery aimed at addressing unmet medical needs. Their core product offerings include an array of compounds in various stages of development targeting diseases with significant medical gaps, such as certain cancers. The end users primarily encompass healthcare providers and patients suffering from these conditions, with particular emphasis on therapeutic solutions that enhance patient health and wellbeing. J-Pharma's products are marketed primarily in Japan, the United States, and Europe, reflecting their commitment to addressing critical health challenges on a global scale.J-Pharma generates revenue through partnerships and collaborations with hospitals, research institutions, and other pharmaceutical companies, focusing on B2B transactions. The company’s transactions are structured around collaborative research agreements and clinical trial partnerships, allowing it to leverage resources and expertise for drug development. These partnerships often involve shared costs and co-development of proprietary drugs, which are positioned for commercialization following successful clinical trials. The company's flagship product, an LAT1 inhibitor named "Nanblanrat," is currently undergoing clinical trials with the potential for future sales following regulatory approvals. Specific pricing plans and transaction details are not publicly disclosed, as J-Pharma's focus remains on advancing its pipeline and addressing crucial therapeutic needs. The company will use the March 2026 IPO funding to strengthen its management, accelerate pipeline development, and maximize medium- to long-term corporate value.

## Funding rounds

- Series F, Jul 7, 2025, $3.3M — Mizuho Capital, Kepple Group, BP Capital
- Series E, Apr 1, 2025, $25M — UntroD Capital, FFG Venture Business Partners, JIC Venture Growth Investments, QR Investment, Fujita Innovation Capital, Governance Partners, SIIF Impact Capital
- Series E, Oct 5, 2023, $6.2M — SIIF Impact Capital
- Series D, Jul 30, 2021, $5.5M — JIC Venture Growth Investments
- Series D, Jan 7, 2021, $4.8M — Eight Roads Ventures, F-Prime Capital
- Series D, Jul 30, 2020, $14M — Sansei Capital Investment, Life Science Venture Capital, Japan Venture Capital Association, Mitsubishi UFJ Capital, Mizuho Capital, Fidea Capital, Osaka University Venture Capital, KSP, QB Capital, Newton Biocapital Partners, Ohara Pharmaceutical Co.,Ltd., KNC Laboratories Co., Ltd., KISCO, Spera Pharma, Inc., SR D Holdings Co., Ltd., Iwagin Business Creation Capital Co., Ltd.
- Series C, Aug 27, 2019, $6.7M — Iwagin Jigyo Souzou Capital
- Series A, Apr 9, 2018, $0.9M — Iwagin Jigyo Souzou Capital

## Investors

- Iwagin Jigyo Souzou Capital (https://capitalatlas.ai/funds/iwagin-jigyo-souzou-capital) — Series A, Series C
- Sansei Capital Investment (https://capitalatlas.ai/funds/sansei-capital-investment) — Series D
- Life Science Venture Capital (https://capitalatlas.ai/funds/life-science-venture-capital) — Series D
- Japan Venture Capital Association — Series D
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series D
- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series D, Series F
- Fidea Capital (https://capitalatlas.ai/funds/fidea-capital) — Series D
- Osaka University Venture Capital (https://capitalatlas.ai/funds/osaka-university-venture-capital) — Series D
- KSP (https://capitalatlas.ai/funds/ksp) — Series D
- QB Capital (https://capitalatlas.ai/funds/qb-capital) — Series D
- Newton Biocapital Partners (https://capitalatlas.ai/funds/newton-biocapital-partners) — Series D
- Ohara Pharmaceutical Co.,Ltd. — Series D
- KNC Laboratories Co., Ltd. — Series D
- KISCO — Series D
- Spera Pharma, Inc. — Series D
- SR D Holdings Co., Ltd. — Series D
- Iwagin Business Creation Capital Co., Ltd. — Series D
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series D
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series D
- JIC Venture Growth Investments (https://capitalatlas.ai/funds/jic-venture-growth-investments) — Series D, Series E
- SIIF Impact Capital (https://capitalatlas.ai/funds/siif-impact-capital) — Series E
- UntroD Capital — Series E
- FFG Venture Business Partners (https://capitalatlas.ai/funds/ffg-venture-business-partners) — Series E
- QR Investment (https://capitalatlas.ai/funds/qr-investment) — Series E
- Fujita Innovation Capital (https://capitalatlas.ai/funds/fujita-innovation-capital) — Series E
- Governance Partners — Series E
- Kepple Group (https://capitalatlas.ai/funds/kepple-group) — Series F
- BP Capital — Series F